MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
BioSpace,
6 min read First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung…